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ABSTRACT: Pro-inﬂammatory protein S100A9 was estab-
lished as a biomarker of dementia progression and compared
with others such as Aβ1−42 and tau-proteins. CSF samples from
104 stringently diagnosed individuals divided into ﬁve
subgroups were analyzed, including nondemented controls,
stable mild cognitive impairment (SMCI), mild cognitive
impairment due to Alzheimer’s disease (MCI-AD), Alz-
heimer’s disease (AD), and vascular dementia (VaD) patients.
ELISA, dot-blotting, and electrochemical impedance spectros-
copy were used as research methods. The S100A9 and Aβ1−42
levels correlated with each other: their CSF content decreased
already at the SMCI stage and declined further under MCI-
AD, AD, and VaD conditions. Immunohistochemical analysis also revealed involvement of both Aβ1−42 and S100A9 in the
amyloid-neuroinﬂammatory cascade already during SMCI. Tau proteins were not yet altered in SMCI; however their contents
increased during MCI-AD and AD, diagnosing later dementia stages. Thus, four biomarkers together, reﬂecting diﬀerent
underlying pathological causes, can accurately diﬀerentiate dementia progression and also distinguish AD from VaD.
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Detection and quantiﬁcation of disease-associated proteinsin the cerebrospinal ﬂuid (CSF) is increasingly important
for the diagnosis, stratiﬁcation, and consequent treatment of
numerous neurodegenerative disorders, including Alzheimer’s
disease (AD) and vascular dementia (VaD). CSF is a sensitive
indicator of hazardous pathological processes in the brain
tissues, reﬂecting the delicate shifts in protein homeostasis.1
This is particularly important because neurodegenerative
syndromes may have potentially diﬀerent underlying molecular
and cellular causes. The detection of corresponding disease-
associated proteins in CSF sheds light on the disease
pathologies and enables us to distinguish them. Early detection
of neurodegenerative pathology is particularly important
because disease-modifying treatments have a higher potential
to slow disease progression when initiated very early, in the
predementia and potentially even presymptomatic phases
before amyloid plaques and neurodegeneration become too
widespread. This may provide a window of opportunity to limit
or reverse these harmful processes. CSF biomarkers may also
reﬂect the cellular and tissue responses to therapeutic
treatments and enable us to monitor and guide the progress
of therapeutic interventions.
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Here we have conducted extensive studies on 104 CSF
samples from nondemented controls and stringently diagnosed
patients with diﬀerent degrees of dementia, progressing from
stable mild cognitive impairment (SMCI), to mild cognitive
impairment due to AD (MCI-AD), and ﬁnally to AD or VaD.
We have focused on the detection in CSF of pro-inﬂammatory
S100A9 protein and compared its contents with an established
AD biomarker triad including Aβ1−42 (a major amyloidogenic
peptide associated with AD), total human tau (H-tau), and tau
phosphorylated at Thr181 (P-tau) (proteins, reﬂecting axonal
degeneration and increased tau phosphorylation, respec-
tively).2,3 Indeed, Aβ peptides are viewed as major contributors
to the amyloid cascade in AD. The brain tissues aﬀected by AD
contain soluble and insoluble amyloid assemblies of Aβ
peptides, both of which may constitute an underlying cause
of dementia.4,5 H-tau and P-tau are microtubule-associated
proteins expressed in neurons, and P-tau is a major component
of abnormal intraneuronal aggregates observed in numerous
tauopathies, including AD. To date, apart from Aβ and tau
pathologies, inﬂammation is also considered to be at the core of
major degenerative diseases of later life, including AD.6,7 Even
in the absence of speciﬁc pathological lesions, inﬂammatory
gene expression increases during aging in humans and also in
animal models.8,9 Thus, inﬂammation may prove central to
therapeutic interventions in neurodegenerative diseases as well
as in general antiaging strategies. The role of inﬂammation in
AD is supported by a sharp induction of inﬂammatory
mediators in disease-aﬀected brain tissues.7 Recently it was
found that a missense mutation in TREM2 renders microglia
overactive to brain Aβ pathology and increases risk of AD by 4-
fold.10 Epidemiological and experimental studies demonstrated
that non-steroidal anti-inﬂammatory drugs markedly reduce the
age-related prevalence of AD.11,12 These drugs can slow
amyloid deposition by mechanisms that are still not fully
understood.
Pro-inﬂammatory S100 proteins are increasingly recognized
as important contributors to inﬂammation-related neuro-
degeneration and aging.9 The abundance of S100a8 and
S100a9 mRNA was shown to be a robust feature of aging in
mammalian tissues, including CNS.9 Among them S100A9
speciﬁcally was implicated in neurodegenerative diseases, that
is, signiﬁcantly increased microglial expression of S100A9 was
observed in the temporal cortex of both familial and sporadic
AD compared with old and young controls.13 S100A9 was also
found in hippocampal and cortical neurons in AD, where it was
colocalized with Aβ peptide.14 Interestingly, S100A8, another
protein from the S100 family, which is able to form a
heterocomplex with S100A9, were not found to be involved in
the neuroinﬂammatory cascade.13,14 We have shown that
S100A9 is intrinsically amyloidogenic and in vitro it forms
cytotoxic amyloid oligomers, protoﬁbrils, and ﬁbrils as readily
as Aβ1−40 and Aβ1−42 peptides.
14 Importantly, S100A9 and Aβ
are able to coaggregate with each other both in vitro and in
vivo.14 In vitro, depending on their molar ratio, they form
together signiﬁcantly larger micrometer-scale ﬁbrillar, spherical,
and nonstructured aggregates compared with each polypeptide
incubated alone.14 Consequently coaggregation can mitigate
the amyloid cytotoxicity of both partners as well as S100A9
pro-inﬂammatory signaling properties. In the AD brain tissues,
both Aβ and S100A9 were found to be colocalized in multiple
amyloid plaques, indicating that due to its inherent
amyloidogenicity S100A9 can contribute to amyloid plaque
formation together with Aβ.14 These emphasize the role of
S100A9 in the AD amyloid−neuroinﬂammatory cascade and
neurodegeneration.14 Therefore, the comparison of the
contents of S100A9, Aβ1−42 and other biomarkers in CSF
may reﬂect their involvement in pathological underlying
mechanisms of AD and disease progression.
■ RESULTS AND DISCUSSION
S100A9 was implicated in pathology of advanced AD as
discussed above,14 and here we examined whether S100A9 is
involved in the disease pathology already at the SMCI stage.
Immunohistochemical analysis with S100A9 and Aβ1−42
antibodies of the cerebellum tissues of a patient diagnosed
with SMCI showed immunopositive plaques of both Aβ1−42
peptide (Figure 1A) and S100A9 (Figure 1C). Aβ1−42 and
S100A9 were not colocalized, however, forming separate tissue
deposits. Strong positive immunostainings with both Aβ1−42
(Figure 1B) and S100A9 (Figure 1D) antibodies were detected
also in numerous neuronal cells, demonstrating elevated
presence of both polypeptides. The staining patterns indicating
the colocalization of Aβ1−42 and S100A9 were overlapped in
some but not in all immunopositive neurons. By contrast, the
presence of S100A8 extracellular and intracellular deposits was
not detected in the same SMCI tissues (Figure S1A).
Immunohistochemical analysis of the nondemented cerebellum
using Aβ1−42, S100A9, and S100A8 antibodies (Figure S1B−D)
Figure 1. Immunohistochemical analysis of SMCI cerebellum by using Aβ1−42 and S100A9 antibodies. Accumulation of Aβ1−42 and S100A9 in
plaques (A, C) and neurons (B, D). Scale bars are 50 μm.
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did not reveal any speciﬁc immunostaining. This indicates that
S100A9, but not S100A8, plays a role in the amyloid−
neuroinﬂammatory cascade, accumulating both in the precursor
plaques and intracellularly already at the SMCI stage.
Therefore, in our further studies we have focused on S100A9
as a prospective MCI/AD biomarker linked to its underlying
pathology, such as the amyloid−neuroinﬂammatory cascade.14
To this end, we have evaluated how CSF changes of S100A9
and the core AD triad, Aβ1−42, H-tau, and P-tau, reﬂect the
progression of dementia. The CSF level of S100A9 was
evaluated using two independent methods, dot-blot analysis
and electrochemical impedance spectroscopy (EIS). Signiﬁ-
cantly lower S100A9 content was found by both methods in the
AD group versus controls (Figure 2A,B). The receiver
operating characteristic (ROC) curve analysis also conﬁrmed
that S100A9 has an excellent diagnostic potential in distinguish-
ing AD from controls (Figure 2C).
Our next step was to diﬀerentiate the CSF content of
S100A9 in the subgroups with various degrees of cognitive
impairment starting from SMCI and proceeding to MCI-AD
and AD. For this purpose, we have used dot-blot analysis,
which demonstrated high sensitivity and consistency in
evaluation and required a small amount of samples (Figure
3A). We have observed pronounced and statistically signiﬁcant
diﬀerences in the S100A9 levels between all demented groups
and controls; the corresponding mean values are presented in
Table 1. Importantly, the content of S100A9 was decreased
signiﬁcantly already in the SMCI group compared with
controls. In the MCI-AD group, the S100A9 levels were
decreased further, eﬀectively reaching those characteristic for
AD individuals. CSF of both AD and VaD patients were
characterized by similar S100A9 levels, though broader
distribution of values were observed in the VaD subgroup
(Figure 3B). These results were further validated by ELISA
measurements performed on the pooled CSF samples for each
subgroup (Figure 3B). We observed eﬀectively the same trend
within the error of measurements as with the dot-blot analysis.
Moreover, the changes of both Aβ1−42 and S100A9 levels
followed the same trend throughout dementia stages (Figure
3). Similar to S100A9 measurements, the SMCI group showed
intermediate values of Aβ1−42 content compared with those for
nondemented controls and AD patients (Figure 3C, Table 1).
The MCI-AD, AD, and VaD subgroups were characterized by a
similar range of Aβ1−42 with the higher spread of values for
VaD, resembling in this regard the corresponding observations
for S100A9 (Figure 3B,C). The covariate analysis also
demonstrated a correlation between the content of Aβ1−42
and S100A9 across the whole CSF sample set with a correlation
coeﬃcient of 0.38, p < 0.05 (Figure 3F). The decrease of Aβ1−42
was reported previously for a similar AD cohort.3 The
concomitant decrease of S100A9 and Aβ1−42 in CSF during
progressing dementia starting from SMCI could be related to
their joint amyloid aggregation in the aﬀected brain tissues,14
which ultimately lead to their depletion from CSF. Because
S100A9 is a pro-inﬂammatory cytokine, our ﬁndings indicate
also that inﬂammatory processes play critical role in the
development of cognitive impairment, starting from early stages
such as SMCI.
Using Western blot analysis with S100A9 antibodies, we
examined whether S100A9 is present in CSF in a low molecular
weight or aggregated form (Figure S2). The S100A9 species in
pooled CSF samples from the control, SMCI, AD, and VaD
subgroups were compared with freshly dissolved recombinant
S100A9 (Mw 13.2 kDa). Recombinant S100A9 was charac-
terized by two bands corresponding by their molecular weight
to monomer and dimer, respectively. By comparison, in the
CSF samples S100A9 was present as a dimer, and this dimer
displayed resistance to both SDS and reducing agent treat-
ments. Because in AD CSF the amount of S100A9 was reduced
compared with controls, the intensity of its Western blot band
was at the limit of detection. The homodimer is the most
common form of S100A9 in biological samples,14 unless it
forms heterodimer or heterotetramer with S100A8.15
Interestingly, the level of another inﬂammatory protein,
S100A8, did not vary in CSF of all studied subgroups (Figure
S3). Though S100A8 and S100A9 form heterocomplexes under
various inﬂammatory conditions within the body,15,16 our
results imply that they can exist separately and fulﬁll
independent functions under neurodegenerative conditions.
While S100A9 was shown to be a critical factor in the
inﬂammation-associated neurodegeneration cascade,14 S100A8
is not apparently involved in this process.
By contrast, the CSF levels of H-tau and P-tau did not
change in SMCI and showed an opposite trend compared with
S100A9 and Aβ1−42 at later stages of the dementia progression,
that is, their levels increased signiﬁcantly in the MCI-AD and
AD subgroups but not in the subgroup with VaD (Figure
3C,D). In AD, the pathological accumulation of tau appears to
Figure 2. CSF S100A9 as a biomarker for AD. Levels of S1009 in CSF in AD patients and controls determined by dot-blot analysis (A) and EIS (B).
Data is presented as box plots. Box-plots include from 25% to 75% of all measurements; central squares indicate the mean value for each group, the
line drawn across the box represents the median value, and the whiskers indicate the distribution from 10% to 90%; **p < 0.001, *p < 0.01. (C)
ROC curve based on dot-blot measurements to evaluate S100A9 as a biomarker for AD. Area under the curve is 0.92, 95% conﬁdence interval width
is 0.11, p < 0.001. Dashed line corresponds to the area under the curve equal to 0.5, indicative that the measured parameter has no diagnostic value.
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be a downstream eﬀect of Aβ aggregation, though the
relationship between Aβ and tau pathologies can be more
complex.17,18 Intracellular tau aggregates are highly toxic
leading to increasing neuronal cell loss, which may be reﬂected
in the rise of their CSF level at the later dementia stages such as
MCI-AD and AD. Summarizing, S100A9, Aβ1−42, and tau
proteins taken together can be used as highly potent
biomarkers able to diﬀerentiate accurately various phases of
dementia starting as early as SMCI. These biomarkers,
reﬂecting diﬀerent underlying pathological causes, can map
Figure 3. Measurements of CSF biomarkers during dementia progression from SMCI to MCI-AD, AD, and VaD. Levels of S100A9 measured by
dot-blot analysis in individual samples (A) and by ELISA in the pooled samples (B). ELISA measurements of Aβ1−42 (C), H-tau (D), and P-tau (E)
contents in individual samples. Data is presented as box plots as described in Figure 1; **p < 0.0001, *p < 0.005. ELISA results for the pooled
samples corresponding to each subgroup are presented as columns with error bars corresponding to standard deviations (SD). (F) Correlation
between the levels of Aβ1−42 and S100A9 across all studied samples. The values corresponding to healthy controls are shown by open circles, those to
AD patients by open triangles, and those to SMCI, MCI-AD, and VaD by black squares.
Table 1. Mean Levels of Studied Biomarkers in CSF of
Demented Patients and Controls
groups
S100A9 (SD),
nM
Aβ1−42 (SD),
nM
H-tau (SD),
pM
P-tau (SD),
pM
controls 0.87 (0.29) 0.21 (0.06) 8.6 (2.5) 1.8 (0.6)
SMCI 0.55 (0.25) 0.16 (0.06) 8.6 (2.9) 1.6 (0.6)
MCI-AD 0.34 (0.08) 0.10 (0.02) 13.7 (1.9) 2.6 (0.4)
AD 0.40 (0.18) 0.10 (0.03) 18.1 (6.8) 2.9 (1.0)
VaD 0.39 (0.14) 0.14 (0.05) 8.5 (2.8) 1.4 (0.6)
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dementia progression with a high accuracy and also potentially
diﬀerentiate AD from VaD. It is important to note that none of
these biomarkers, including the most studied Aβ peptide
reﬂecting cerebral β-amyloidosis in MCI and AD, will be used
in isolation to make a diagnosis of AD dementia, MCI, or
“normal aging.” Each biomarker is used to assess the
corresponding underlying pathophysiology of subjects. Recent
advances in research diagnostic criteria for AD provided better
deﬁnition of its clinical phenotypes and also integrated
biomarkers into the diagnostic process, covering all stages of
the disease.19−21 These criteria provided a new conceptual
framework stating that AD could be diagnosed based on the
combination of a clinical phenotype of episodic memory
disturbances and one or more abnormal AD biomarkers
including CSF biomarkers (Aβ and tau proteins), volumetric
MRI, and amyloid PET. Here we suggest that S100A9, as the
CSF biomarker of amyloid−neuroinﬂammatory cascade, should
also enter this arena. Methodologies and diagnostic procedures
described here can be eﬀectively implemented in clinical
practice to date. Our ﬁnding of S100A9 diagnostic potential
indicates also that the neuroinﬂammatory proteins should be
more widely explored for diagnostic purposes and especially in
the early or even preclinical stages of neurodegeneration.
■ METHODS
Human Subjects. CSF samples from 104 individuals were
analyzed. A selected cohort of 84 participants with diﬀerent stages
of dementia and nondemented controls was recruited at the Falköping
Memory Clinic. They were all stringently diagnosed as described
previously.3 In addition, 20 nondemented participants treated as
controls were recruited from the Umea ̊ University Hospital. The
controls were patients whose CSF samples were collected for analysis
of diﬀerent disorders other than neurodegenerative diseases, including
headache, polyneuropathy, neurogenic pain, dizziness, and fatigue. The
characteristics of human participants are presented in Table 2.
Tissue Samples. The brain tissues were collected at the Medical
Institute, Sumy State University, Ukraine. The cerebellum tissues from
a SMCI patient, a 43 y.o. male deceased from liver cirrhosis, and from
a neurologically healthy individual, a 48 y.o. female deceased from
Wegener’s granuloma, were analyzed. SMCI was diagnosed based on
the respective clinical criteria and cognitive performances examined in
a series of neuropsychological tests including mini-mental state
examination.22 All tissues were paraﬃn-embedded and microtome-
sectioned to 4 μm thick slices.
CSF Collection. Lumbar puncture for collection of CSF samples
was performed following the established procedure as described
previously.23 Each CSF sample was centrifuged at 2000g for 10 min;
supernatants were frozen in 0.5 mL aliquots in polypropylene tubes
and stored at −80 °C.
Immunohistochemistry. Immunohistochemistry on the tissue
sections was performed as described previously.14 The following
antibodies were used: Aβ1−42 (mouse monoclonal, ab11132, 1 in 200,
Abcam), S100A8 (goat polyclonal, sc-8112, 1 in 100, St Cruz
Biotechnology), and S100A9 (rabbit polyclonal, sc-20173, 1 in 100, St
Cruz Biotechnology). The tissues were scanned by a Panoramic SCAN
slide scanner 250 (3D Histech).
Dot-Blot Analysis. We used as little as 3 μL of CSF for analysis,
taking all aliquots in triplicate. The contents of S100A8 and S100A9
were evaluated by dot-blot assay involving primary antibodies against
human S100A8 (goat polyclonal, sc-8112, 1 in 2000, St Cruz
Biotechnology) and human S100A9 (mouse monoclonal, MAB5578,
1 in 2000, R&D Biosciences), respectively.
EIS. Twenty AD and nine control CSF samples were subjected to
EIS measurements. CSF volumes of 5 μL were analyzed in triplicate
for each sample.
ELISA. CSF Aβ1−42, H-tau, and P-tau concentrations were measured
by Innotest ELISA kits (Fujirebio) as previously described.23 The
content of S100A9 was assessed by a newly developed sandwich
ELISA.
Statistical Analysis. OriginPro 8.0 software was used for the
statistical analysis. The comparison between groups was carried out by
using a two-tailed Student’s t test for unequal variance. Spearman’s
coeﬃcient was used to evaluate the correlation between two variables.
The level of signiﬁcance was set at p < 0.05.
Ethical Approval. The study was conducted according to
Declaration of Helsinki principles and approved by the medical ethics
committees of University of Gothenburg, Umea ̊ University, Sweden,
and Medical Institute, Sumy State University, Ukraine. All subjects
gave their written informed consent prior investigation. Participants
were identiﬁed by number, not by name.
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AD, Alzheimer’s disease; EIS, electrochemical impedance
spectroscopy; H-tau, total human tau; MCI-AD, mild cognitive
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operating characteristic; SMCI, stable mild cognitive impair-
ment; P-tau, phosphorylated tau; VaD, vascular dementia
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